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AbstraetmLiver-directed gene therapy is being considered in the O'eatment of inherited metabolic 
diseases. One approach we are considering is the transplantation of autologous hepatocytes that 
have been genetically modified with recombinant retroviruses ex vivo. We describe, in this report, 
techniques for isolating human hepatocytes and efficiently transducing recombinant genes into 
primary cultures. Hepatocytes were isolated from tissue of four different donors, plated in primary 
culture, and exposed to recombinant retroviruses expressing either the LacZ reporter gene or the 
cDNA for rabbit LDL receptor: The efficiency of gene transfer under optimal conditions, as 
determined by Southern blot analysis, varied from a maximum of one proviral copy per cell to a 
minimum of O. 1 proviral copy per cell. Cytochemical assays were used to detect expression of the 
recombinant derived proteins, E. coli ~-gaIactosidase and rabbit LDL receptor. Hepatocytes 
transduced with the LDL receptor gene expressed levels of receptor protein that exceeded tile 
normal endogenous levels. The ability to isolate and genetically modify human hepatocytes, as 
described in this report, is an important step towards the development of liver-directed gene 
therapies in humans. 
INTRODUC~ON 
Somatic gene therapy is being consid- 
ered in the treatment of a variety of diseases 
(i). We are developing approaches for 
treating inherited metabolic disorders in 
which therapeutic genes are transferred into 
hepatocytes (2). One specific strategy, called 
ex vivo gene therapy, is based on transplanta- 
tion of autologous, genetically modified, 
hepatocytes. Our proposed protocol for 
human applications of ex vivo gene therapy is 
summarized below. Liver tissue will be 
harvested from a patient and collagenase 
perfused ex vivo to release a suspension of 
hepatocytes. The viable hepatocytes will be 
plated in culture and exposed to stocks of 
recombinant retroviruses capable of effi- 
ciently transducing recombinant genes into 
the genome of the recipient hepatocytes. The 
genetically modified hepatocytes will then be 
harvested and transplanted into the patient 
from which they were derived. 
The feasibility of ex vivo liver-directed 
gene therapy in humans is supported by 
extensive experiments in small animal mod- 
els. We and others have used recombinant 
retroviruses to transduce a variety of genes 
into primary cultures of hepatocytes derived 
from mouse (3), rat (4, 5), and rabbit (6, 7). 
Various techniques for transplanting hepato- 
cytes have been described; however, most of 
these approaches have little relevance to 
therapeutic applications because of limita- 
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tions in the capacity, durability, or function 
of the engrafted cells (for example see 8, 9). 
More recent studies that transplant hepato- 
cytes into the portal circulation or the 
peritoneal cavity on microcarrier beads ap- 
pear more promising (10-13). 
The specific disease we are considering 
for early human applications of liver-directed 
gene therapy is homozygous familial hyper- 
chotesterolemia (FH). This disorder is caused 
by a deficiency" of LDL receptors and is 
associated with severe hypercholesterolemia 
and premature coronary heart disease (14). 
Orthotopic liver transplantation leads to 
marked improvement in the dyslipidemia of 
FH, suggesting that liver-directed gene trans- 
fer may be sufficient for some level of 
therapeutic efficacy (15, 16). We have used 
an animal model of FH, the Watanabe 
heritable hyperlipidemic (WHHL) rabbit, to 
develop ex vivo gene therapies directed to 
liver (6, 17). In a previous study, we isolated 
WHHL hepatocytes, established primary 
cultures, and used recombinant retroviruses 
to transduce functional LDL receptor genes 
into the hepatocytes. Transplantation of the 
genetically corrected hepatocytes into alloge- 
neic WHHL recipients was associated with 
transient diminutions in serum cholesterol 
(17). 
Essential to the development of liver- 
directed gene therapy in humans are meth- 
ods for isolating viable human hepatocytes 
and efficiently transducing therapeutic genes 
into the hepatocytes. We describe in this 
report our experience with hepatocyte isola- 
tion from livers from four donors and the 
genetic modification of these cells with 
recombinant retroviruses that express dif- 
ferent genes. 
M A T E R I A L S  A N D  M E T H O D S  
Hepatocyte Isolation and Primary Cultures. 
Liverswere perfused with UW solution or 
Euro-Collins solution and stored at 4°C prior 
to hepatocyte isolation. A portion of the liver 
(60-1.24 g) was removed and l x Leffert's 
solution (18), pH 7.4, containing 0.5 mM 
EGTA was perfused into major vessels 
through a 16-gauge angiocath for 10 min. 
This was followed by perfusion with l x 
Leffert's solution, pH 7.4, without EGTA for 
5 min, and then l x Leffert's, pH 7.4, 
containing 5 mM CaCt2, 5 mg/ml BSA 
(fraction V), and 0.5 mg/ml collagenase D 
(Boehringer Mannheim) for 18-24 min. The 
collagenase perfusion was terminated when 
the liver softened and began to dissociate. 
All solutions were filter sterilized prior to use 
and oxygenated at 37°C during the perfu- 
sions. Flow rates varied from 100 to 125 
ml/min. The perfused liver was teased apart 
with a rubber policeman and forceps and 
filtered through a presterilized 85-~m nylon 
mesh at 4°C into a sterile flask containing 
RPMI 1640 medium with 10% fetal bovine 
serum and 1% penicillin/streptomycin (me- 
dium A). The filtered hepatocytes were 
pelleted by centrifugation three times at 50g 
tbr 1 min, resuspended in medium A, and 
viable cells were quantified by exclusion of 
trypan blue. 
Ilepatocytes were plated at 2 or 4 x 106 
cells/10-cm plate overnight in hormonally 
defined medium (HDM) containing 10% 
fetal calf serum onto Primaria plates (19). 
Each subsequent day the media was replaced 
with fresh HDM without serum. 
Retroviral-Mediated Gene Transfer. Am- 
photropic viral producer cell lines made 
from the BAG (20) and AFP-BA-rLDLR 
(Grossman et al., in preparation) vectors 
were used in these experiments. Fresh virus 
was harvested from confluent plates of viral 
producers in DMEM containing 10% calf 
serum and 1% penicillin/streptomycin, 
supplemented with 8 ~xg/ml of polybrene, 
and placed directly onto the hepatocyte 
cultures for a 16-h period beginning 48 h 
(day 2) or 72 h (day 3) after initial plating. 
DNA and RNA Analyses. Cultures were 
analyzed 48 h after infection for the presence 
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of proviral DNA and viral-derived RNA. 
Total cellular DNA was harvested, restricted 
with endonucleases, and analyzed by the 
method of Southern using probes derived 
from either a 1067-bp PstI fragment from 
rabbit LDL receptor cDNA (for LDL recep- 
tor-transduced cultures) or a 877-bp ClaI to 
BglII fragment from the lacZ gene (for 
BAG-transduced cultures) (6). Total cellular 
RNA was harvested and analyzed by blot 
analysis as described (6). Filters containing 
RNA from LDL receptor-transduced cells 
were probed with the fragment described for 
the Southern blot studies. 
Cytochemical Assays for Recombinant 
Gene Expression. Hepatocytes were assayed 
for recombinant gene expression 48 h after 
infection. BAG-transduced hepatocytes were 
subjected to the chromogenic histochemical 
assay for [3-galactosidase (20). LDL receptor- 
transduced cells were incubated with fluores- 
cent-labeled DiI-LDL (10 txg/ml) for 6 h, 
washed in PBS, and visualized under phase- 
contrast and fluorescence microscopy (6). 
RESULTS AND DISCUSSION 
A portion of liver tissue from four 
different donors, labeled Zl  through 7_,4, was 
used for hepatocyte isolation. Salient fea- 
tures of the patients and the hepatocyte 
isolations are summarized in Table 1. Liver 
sections from three of the donors were 
available because the organ had been surgi- 
cally reduced prior to transplantation; the 
fourth organ had been harvested but not 
used for transplantation because the donor 
was hemodynamically unstable and had 
elevated liver function tests. The organs were 
perfused with UW solution (Z1, Z2, Z3) or 
Euro-Collins solution (Z4) and stored for 
variable periods of time prior to hepatocyte 
isolation (30 min to 36 h). The age of the 
donors ranged from 22 months to 44 years. 
Hepatocytes were isolated by collage- 
nase perfusion of the major vessels using a 
modification of the technique shown to be 
successful in isolating hepatocytes from 
rabbits (17). The viability of recovered 
hepatocytes ranged from 85% to 98%, while 
the recovery of viable cells ranged from 3 to 
33 x 106 cells/g wet weight of tissue. The 
hepatocytes were plated overnight in HDM 
containing bovine fetal serum onto Primaria 
tissue culture plates and were subsequently 
maintained in serum free HDM. Figure ! 
presents serial phase-contrast micrographs 
of cultures from patient Z2. Plating effi- 
ciencies ranged from approximately 50% to 
greater than 95%. The cultures were seeded 
at various subconfluent densities and rapidly 
grew to confluence within 72 h of the initial 
Table 1. Summary of Organ Donors and Hepatocyte Isolations 
Z1 Z2 Z3 Z4 
Donor 
Age 22 months 4 years 44 years 18 years 
Sex male female male male 
Clinical stable stable stable shock, increased LFTs 
Organ reduction reduction reduction unsuitable for TxJ' 
Perfusate UW UW UW Euro-Collins 
Time ° 16 h 2 h 36 h 30 min 
Isolation and culture 
Weight (g) ~ 60 7t ~ 60 t24 
Viability (%) 89 98 85 92 
Recovery (x 10 ~) 2 1.5 0.2 0.5 
Plating efficiency (%) > 95 50 > 95 > 95 
~Time between organ harvest and hepatocyte isolation. 
~The donor was hemodynamically unstable and had elevated liver function tests prior to organ harvest. 
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Fig. 1. Micrographs of cultured hepatocytes. 
Hepatocytes from patient Z2 were plated at 4 
x 106/10-cm plate and maintained in culture 
as described in Materials and Methods. Micro- 
graphs of the culture were taken one, two, 
three, and four days after the initial seeding 
Magnification is 100 x. 
plating. Hepatocytes were maintained in 
primary culture for a total of four to five days. 
Experiments were performed to maxi- 
mize the efficiency of retroviral-mediated 
gene transfer. Two recombinant retroviruses 
were used to infect the primary cultures from 
each patient; both types of virus were 
produced in the amphotropic packaging cell 
line '~ crip (20). One recombinant virus was 
produced from the previously described 
BAG vector that expresses the lacZ gene 
from a transcript initiated at the 5' LTR and 
a gene encoding Neo from SV40 sequences 
located internal to the viral transcriptional 
unit (20). Another recombinant virus was 
produced from a vector called AFP-BA- 
rLDLR, which expresses rabbit LDL recep- 
tor from a transcript initiated at promoter 
sequences that are derived from the chicken 
13-actin gene along with enhancer sequences 
from the mouse ot-fetoprotein gene (Gross- 
man et al., in preparation). The relative titer 
of each virus was estimated by infecting 
subconfluent plates of NIH3T3 cells and 
harvesting total cellular DNA for Southern 
blot analysis. BAG-infected cells contain 
approximately 0.5 copy of proviral DNA 
per cell, while LDL receptor-infected cells 
contain approximately one copy of proviral 
DNA per cell. 
Based on our previous experiences with 
primary cultures of rat (5) and rabbit (6, 17) 
hepatocytes, we developed a protocol for 
efficiently infecting human primary hepato- 
cytes. The protocol was designed to maxi- 
mize gene transfer and minimize the time the 
hepatocytes are maintained in culture. Hepa- 
tocytes were seeded at different densities (2 
or 4 x 106/10-cm plate) and exposed to the 
viruses for a single 12-h period beginning 48 
h (day 2) or 72 h (day 3) after initial plating. 
Cells were harvested 48 h after completion of 
the infection and total cellular DNA was 
prepared for blot analysis to estimate the 
abundance and integrity of integrated provi- 
ral DNA in the unselected population. 
Representative experiments are presented in 
Fig. 2. Efficiency of gene transfer with the 
LDL receptor virus ranged from a maximum 
of one proviral copy per diploid genome for 
Zl  to a minimum of 0.1 proviral copy per 
diploid genome for Z2. Infection efficiency 
was consistently highest when the cells were 
exposed to virus 48 h after plating; density of 
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sures the steady-state level of  recombinan t  
R N A s  (Fig. 3). The  A F P - B A - r L D L R  vector  
contains two transcriptional  units: transcrip- 
tion f rom the 5'  L T R  produces  a 5.6-kb R N A  
responsible for passage of  the virus, while a 
transcript  initiated at the 13-actin p romote r  
produces  a 3.4-kb transcript  responsible for 
translation of  the L D L  receptor  protein.  The  
3' L T R  in the plasmid vector,  which has been  
deleted of  enhancer  sequences,  forms the 
template  for both LTRs  in the integrated 
provirus (21). The rat ionale for this modifica- 
tion is to minimize the L T R  transcript  and 
maximize the t ranslated 13-actin transcript  in 
Fig. 2. Southern blot analysis of DNA from infected 
hepatocytes. Total cellular DNA (10 b~g) was restricted 
with NheI and analyzed by the method of Southern. The 
figure is organized in the following manner: The left 
columns contain DNA from LDL receptor~infected 
cells; the right columns contain DNA from BAG- 
infected cells, ttepatocytes were plated at 2 or 4 x 106 
and infected on day 2 or day 3. DNAs were analyzed for 
each patient (ZI-Z4). The bottom portion of the figure 
contains DNA (10 txg) from mock-infected hepatocytes 
alone ("Mock") or supplemented with ptasmid DNA 
(7.5 pg) that represents approximately one proviral copy 
per cell ("control"). The proviral derived band is 
indicated by an arrow. The larger band at 10 kb 
represents hybridization to endogenous sequences. 
plating did not  consistently affect the effi- 
ciency o f  gene transfer.  The  absolute level of  
gene transfer  was less with the lower-ti ter 
B A G  virus, a l though the effects of  plating 
density and time of  exposure to virus on gene 
t ransfer  were  similar. 
Expression of  the integrated L D L  recep- 
tor provirus in h u m a n  hepatocytes  was 
studied by R N A  blot analysis, which mea-  
Fig. 3. Northern blot analysis of RNA from infected 
hepatocytes. Total cellular RNA (10 Ixg) was analyzed 
for recombinant transcripts as described in Materials 
and Methods. RNAs from kDL receptor-transduced 
cultures were studied. The figure is organized as 
described for the Southern blots in Fig. 3. The open 
arrow indicates the location of the LTR-directed 5.6-kb 
transcript, the filled arrow indicates the location of the 
f3-actin-directed 3.4-kb transcript. 
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the infected cells. Both the 5.6-kb and 3.4-kb 
recombinant-derived LDL receptor tran- 
scripts were detected in infected hepatocyte 
cultures from each donor. As expected, the 
smaller transcript initiated from the internal 
promoter was more abundant than the larger 
LTR-initiated transcript. 
Hepatocyte cultures transduced with 
either the BAG or the LDL receptor virus 
were analyzed for recombinant gene expres- 
sion using cytochemical analyses (Fig. 4). 
Expression of E. coli [3-galactosidase in the 
BAG-transduced cells was detected with a 
histochemical stain using the chromogenic 
substrate X-gal that produces a diffuse blue 
cytoplasmic precipitate (20). A representa- 
tive X-gal stain of the Zl  infected hepato- 
Fig. 4. Cytochemical analysis of recombinant gene 
expression in transduced hepatocytes. (A) Hepatocytes 
from Z1 plated at 4 x 106 cells/10-cm plate and infected 
on day 2 with BAG virus were subjected to the 
chromogenic assay for 13-galactosidase activity. (B and 
C) Hepatocytes from Z2 plated at 2 x 106 cells/10-cm 
plate and infected on day 3 with LDL receptor virus 
were incubated with fluorescent labeled LDL and a 
representative field was visualized under fluorescent (B) 
and phase-contrast microscopy (C). Magnification is 
100x. 
cytes is shown in Fig. 4A. This analysis 
demonstrated lacZ expression in approxi- 
mately 10-25% of cells, thereby confirming 
the estimate of gene transfer provided by 
Southern blot analysis (0.3 proviral copies 
per cell, see Fig. 2). Expression of recombi- 
nant LDL receptor protein was analyzed 
using an in situ functional assay that detects 
uptake of fluorescent-labeled LDL (6). Mock 
infected hepatocytes demonstrated low lev- 
els of fluorescence representing uptake via 
the endogenous receptors (data not shown). 
Analysis of LDL receptor-transduced hepato- 
cytes from patient Z2 revealed a subpopula- 
tion of highly fluorescent cells comprising 
approximately 20% of the culture (Fig. 4B 
and C). This result indicates that the 
recombinant-derived receptor is functional 
and can be expressed at levels in excess of the 
normal endogenous receptor. 
This study has important implications in 
the development of liver-directed gene thera- 
pies in humans. We describe a technique for 
reproducibly isolating high yields of viable 
hepatocytes. The isolated hepatocytes were 
plated onto tissue culture plastic with high 
efficiency and allowed to expand over a short 
period of time in primary culture to form 
confluent monolayers. The quality of the 
cultures and ability to transduce genes were 
shown to be independent of the age (22 
months to 44 years of age) and sex (three 
males and one female) of the donor and the 
duration of time that the organ was pre- 
served prior to hepatocyte isolation (30 min 
to 36 h). 
The efficacy of ex vivo gene therapy in 
the liver for the treatment of metabolic 
diseases is directly linked to the efficiency of 
genetic reconstitution. The net level of 
genetic reconstitution is related to the 
efficiency of gene transfer, the level of 
recombinant gene expression, and the capac- 
ity of hepatocyte engraftment. We have 
described methods that utilize recombinant 
retroviruses to efficiently and stably trans- 
duce recombinant genes into primary cul- 
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tures of  hepatocytes. Gene  transduction can 
be achieved soon after  the initial seeding 
(i.e., 72 h) thereby minimizing the time the 
hepatocytes are in culture prior to transplan- 
tation. In the case of L D L  receptor,  expres- 
sion of the .recombinant protein actually 
exceeds that of the endogenous protein. 
It is hoped that the techniques of 
hepatocyte isolation and gene transfer de- 
scribed in this report ,  combined with meth- 
ods for transplanting hepatocytes, will pro- 
vide the basis for ex vivo gene therapies for 
inherited metabolic diseases. 
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